Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT06747572
Active, not recruiting Observational

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572 · tracked via the Priya Life Science UK tracker
Sponsor
Vertex Pharmaceuticals Incorporated
Phase
Observational
Started
2024-12-19
Last updated
2026-10-26

Condition(s) studied

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study summary

The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.

Eligibility

Sex
ALL
Min age
12 Years
Max age
65 Years
Healthy volunteers
No
Key Inclusion Criteria: * Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m\^2 * Willing and able to comply with scheduled visits and other study procedures * A pre-existing diagnosis of ADPKD as defined in the protocol Key Exclusion Criteria: * History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD * History of solid organ or bone marrow transplantation or nephrectomy * Ongoing renal replacement therapy or planning to start renal replacement therapy less than or equal to (≤)12 months from the Genotyping Visit in Part A Other protocol defined Inclusion/Exclusion criteria will apply.

Primary outcome measure(s)

  • Part A: Percentage of PKD1 Gene Variant Groups in the ADPKD Population — Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
  • Part A: Weight of Participants Within Each PKD1 Gene Variant Group — Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
  • Part A: Height of Participants Within Each PKD1 Gene Variant Group — Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
  • Part A: Body Mass Index (BMI) of Participants Within Each PKD1 Gene Variant Group — Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
  • Part A: Age of Participants at ADPKD Diagnosis Within Each PKD1 Gene Variant Group — Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)

Trial sites (45)

FacilityCityRegionStatus
Alabama Kidney Research Alabaster Alabama
University of Alabama at Birmingham- Nephrology Research Clinic Birmingham Alabama
Kaiser Permanente - Los Angeles Medical Center Los Angeles California
UCLA Division of Nephrology Los Angeles California
Helen Diller Medical Center at Parnassus Heights San Francisco California
Nephrology & Hypertension Associates, PC Middlebury Connecticut
Yale Nephrology Clinical Research Clinic New Haven Connecticut
Nature Coast Clinical Research - Inverness Inverness Florida
Mayo Clinic - Jacksonville Jacksonville Florida
Emory School of Medicine - Renal Division Atlanta Georgia
Renal Associates, LLC Columbus Georgia
UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology Chicago Illinois
University of Iowa Health Care Medical Center- Nephrology Iowa City Iowa
Clinical & Translational Science Unit (CTSU) - Nephrology Kansas City Kansas
General Clinical Research Center, University of Maryland Baltimore Baltimore Maryland
Tufts Medical Center Boston Massachusetts
Beth Israel Deaconess Medical Center - Nephrology Boston Massachusetts
Quest Research Institute Farmington Hills Michigan
University of Minnesota -Health Clinical Research Unit Minneapolis Minnesota
Mayo Clinic - Rochester Rochester Minnesota
DaVita Clinical Research Las Vegas Nevada
Columbia University Medical Center New York New York
Geisinger Clinic Danville Pennsylvania
Perelman Center for Advanced Medicine - Nephrology Philadelphia Pennsylvania
Nephrology Clinical Trials Center Nashville Tennessee
UVM Medical Center - 1 South Prospect Street Burlington Vermont
Swedish Center for Comprehensive Care Seattle Washington
Universite Catholique de Louvain, Cliniques universitaires Saint-Luc (UCLouvain) Brussels Belgium
Universitaire Ziekenhuizen Leuven Leuven Belgium
St. Joseph's Healthcare - Hamilton Hamilton Canada
MUHC - Montreal Children's Hospital Montreal Canada
Hopital de la Cavale Blanche Brest France
Necker Hospital Paris France
Charité - Klinik für Nephrologie und Intensivmedizin der Berlin Germany
Universitaetsklinik Koeln Department II of Internal Medicine Cologne Germany
UMCG - Nephrology Groningen Netherlands
Erasmus Medisch Centrum - Nephrology Rotterdam Netherlands
FDI Clinical Research - San Juan San Juan Puerto Rico
Hospital Fundacion Jimenez Diaz Madrid Spain
Queen Elizabeth Hospital Birmingham Birmingham United Kingdom

+ 5 more sites — see the full list on the official registry below.

More Vertex Pharmaceuticals Incorporated trials in the UK

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy Recruiting
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) Active, not recruiting
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) Active, not recruiting
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Active, not recruiting
A Long-term Follow-up Study in Participants Who Received CTX001 Enrolling by invitation

Other trials for the same condition

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06747572 on ClinicalTrials.gov ↗ ← All trials in the UK